Home » Topics » Disease categories and therapies » Gastrointestinal

Gastrointestinal
RSS

PEG-Intron at least as effective and safe as Intron A in phase III HCV trial

April 28, 2000

Synergistic anti-HBV combinations under study at Glaxo Wellcome

April 28, 2000

SB researchers design potent and selective 5-HT4 receptor antagonist

April 27, 2000

Newly issued U.S. patent protects Questcor's position in anti-HCV drug discovery

April 27, 2000

Y-27632 demonstrates beneficial effects on hepatic fat-storing cells and hepatic fibrosis

April 26, 2000

Worldwide licensing agreement announced for MKC-733

April 26, 2000

New agents for GI disorders patented by Byk Gulden

April 26, 2000

Zeria updates status of GI pipeline

April 25, 2000

ID Biomedical licenses oral E. coli vaccine technology

April 25, 2000

New controlled-release, microencapsulated HBV vaccine prepared in China

April 24, 2000

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 12, 2026.
Europe’s Alzecure, Orionis in $1B+ deals with Lilly, Novartis
BioWorld
Two companies with European ties signed billion-dollar deals with large pharma firms in the last two days to discover and develop molecular glue drugs, as well as...
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...
Sanofi phase III CIDP quit dents Dianthus; C1 mismatch?
BioWorld
Investors in Dianthus Therapeutics Inc. apparently chose to ignore subtleties in the difference between efforts with that firm’s claseprubart vs. those by...
Jiangsu Nhwa Pharmaceutical patents new κ-opioid receptor antagonists
BioWorld Science
Jiangsu Nhwa Pharmaceutical Co. Ltd. has disclosed κ-opioid receptor antagonists that are potentially useful for the treatment of neurological disorders.